Maze Therapeutics (MAZE) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MeiraGTx (MGTX) has outperformed Maze Therapeutics (MAZE) over the past year, gaining 27.4% versus a loss of 5.8%. Maze Therapeutics is the larger company by market cap ($1.44 billion vs $1.01 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MAZE | MGTX |
|---|---|---|
| Share price | $25.88 | $10.50 |
| Market cap | $1.44B | $1.01B |
| 1-day change | -1.41% | -2.96% |
| YTD return | -36.64% | +36.10% |
| 1-year return | -5.78% | +27.44% |
| 5-year return | — | -24.23% |
| P/E ratio (TTM) | — | 12.07 |
| EPS (TTM) | $-2.48 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $53.65 | $15.35 |
| 52-week low | $21.95 | $6.62 |
| Distance from 52-week high | -51.76% | -31.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +137.64% | +164.29% |
| Average volume | 560.26K | 797.37K |
| Shares outstanding | 55.55M | 96.04M |
| Employees | 141 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed MAZE by 33.2 percentage points over the past year.
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
MAZE vs MGTX FAQ
Which is bigger, Maze Therapeutics or MeiraGTx?
Maze Therapeutics (MAZE) is larger, with a market capitalization of $1.44B compared with $1.01B for MeiraGTx (MGTX).
Which stock has performed better over the past year, MAZE or MGTX?
MGTX returned +27.44% over the past 12 months, compared with -5.78% for MAZE (price return, excluding dividends). Past performance does not predict future results.
Are Maze Therapeutics and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.